HomeSUPN • NASDAQ
Supernus Pharmaceuticals Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 192.10M | 9.34% |
Operating expense | 135.30M | 34.30% |
Net income | -45.12M | -217.20% |
Net profit margin | -23.49 | -207.21% |
Earnings per share | 0.61 | -44.61% |
EBITDA | 33.28M | -31.28% |
Effective tax rate | 22.15% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 281.16M | -30.27% |
Total assets | 1.42B | 5.74% |
Total liabilities | 370.09M | 10.29% |
Total equity | 1.05B | — |
Shares outstanding | 57.34M | — |
Price to book | 2.44 | — |
Return on assets | 1.51% | — |
Return on capital | 1.94% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -45.12M | -217.20% |
Cash from operations | -61.66M | -215.22% |
Cash from investing | 48.71M | 163.25% |
Cash from financing | 21.07M | 585.14% |
Net change in cash | 8.11M | 139.72% |
Free cash flow | 5.13M | -85.60% |
Previous close
$44.90
Day range
$44.52 - $45.60
Year range
$29.16 - $57.65
Market cap
2.60B USD
Avg Volume
1.03M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2005
Headquarters
Website
Employees
674
